Armando Anido

Mr. Anido has served as Chairman and Chief Executive Officer (CEO) of Zynerba Pharmaceuticals since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe Inc., which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before the company's acquisition by Teva. He also served as President and CEO of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Under Mr. Anido's leadership at Auxilium, sales grew from $42 million in 2005 to more than $260 million in 2011. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, where Synagis, an anti-viral for RSV, became a blockbuster product, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He is currently a member of the Board of Directors of AURIS Medical Holding AG and Life Science PA, and he was a member of the Board of Directors of Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.